MedTrace Logo

TAK-114 Single- and Multiple-Dose Phase 1 Study

NCT02286518 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2016-07-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of TAK-114 following single and multiple ascending oral doses in healthy Japanese male participants.

Conditions

  • Clinical Pharmacology

Interventions

DRUG

TAK-114 10 mg capsule

DRUG

TAK-114 matched placebo

Sponsors & Collaborators

Principal Investigators

  • General Manager · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02286518 on ClinicalTrials.gov